ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0536 • ACR Convergence 2024

    A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease

    Claire Mukashyaka1, Xiaodong Wang1, Sujata Arora1, Mason Yamashita1, Allen Poma1 and Tanya Fischer2, 1Zenas BioPharma, Waltham, MA, 2Zenas BioPharma, Waltham, CA

    Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
  • Abstract Number: 0867 • ACR Convergence 2024

    Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis

    Marc Blanchard1, Cinja Koller2, Jules Maglione3, Patrick Hermann1 and Thomas Hügle3, 1Lausanne University Hospital, Lausanne, Vaud, Switzerland, 2Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, 3Lausanne University Hospital, Lausanne, Switzerland

    Background/Purpose: Rheumatoid arthritis (RA) care faces challenges due to a shortage of healthcare providers, an increasing patient population and the remote locations of many patients.…
  • Abstract Number: 0928 • ACR Convergence 2024

    In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects

    monia Maccaferri1, Francesco Zambianchi2, Carlo Salvarani3 and Elisa Pignatti3, 1Azienda Ospedaliero Universitaria di Modena, Modena, Italy, 2Department of Maternal, Child and Adult Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy, 3Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy

    Background/Purpose: Interactions between fibroblast-like synoviocytes (FLSs) and macrophage-like synoviocytes (MLSs) are pivotal in the pathogenesis of RA and PsA. FLSs both activate and are activated…
  • Abstract Number: 0977 • ACR Convergence 2024

    Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older

    Emily Rayens1, Lina Sy1, Lei Qian1, Jun Wu1, Bradley Ackerson1, Yi Luo1, Yanjun Cheng1, Antony Lin1, Zendi Solano1, Justine De Jesus1, Britta Amundsen1, Ana Florea1, Jen Ku1, Elizabeth Chmielewski-Yee2, Driss Oraichi2, Harry Seifert2, Huifeng Yun2 and Hung-Fu Tseng1, 1Kaiser Permanente Southern California, Pasadena, CA, 2GSK, Rockville, MD

    Background/Purpose: Individuals with rheumatoid arthritis (RA) are at higher risk of herpes zoster (HZ) compared to the general population. This interim analysis evaluated the vaccine…
  • Abstract Number: 1032 • ACR Convergence 2024

    Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities

    Alexis Barbut1, Marsha Jackson2, Krista Kowiak2, Julie McIntyre2 and Allen Anandarajah1, 1University of Rochester Medical Center, Rochester, NY, 2University of Rochester Medical Center, Rochester

    Background/Purpose: Rheumatoid Arthritis (RA) is often associated with comorbidities including hypertension, cardiovascular disease, osteoporosis, lung disease, and eye involvement. Studies suggests that the average RA…
  • Abstract Number: 1217 • ACR Convergence 2024

    Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California

    Maggie Hui1, Nicholas Jackson2, Angela Pham1, Keren Chen2, David Elashoff2, ziva Cooper3 and Veena Ranganath4, 1David Geffen School of Medicine at UCLA, Los Angeles, 2UCLA Department of Medicine Statistics Core, Los Angeles, 3UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles, 4UCLA, Los Angeles, CA

    Background/Purpose: Approximately 12-20% of Rheumatology patients use cannabis (Fitzcharles 2020, Wipfler 2022, Rampakakis 2023). Despite the legalization of medical cannabis in California more than 2…
  • Abstract Number: 1334 • ACR Convergence 2024

    Assessing the Performance of Validated Frailty Instruments in Veterans with Rheumatoid Arthritis (RA)

    Kylie Riggles1, Hannah Brubeck2, Riley Bass3, Courtney Loecker4, Punyasha Roul5, Bryant England6, Elizabeth Wahl7, James Andrews8, Namrata Singh9, Joshua Baker10, Patti Katz11, Dolores Shoback12, Jose Garcia13, ariela orkaby14 and Katherine Wysham15, 1VA Puget Sound Health Care System, Bellevue, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3VA Puget Sound Health Care System, Gig Harbor, WA, 4University of Nebraska, Lincoln, NE, 5UNMC, Omaha, NE, 6University of Nebraska Medical Center, Omaha, NE, 7VA Puget Sound Healthcare System, Seattle, WA, 8University of Alabama at Birmingham, Birmingham, AL, 9University of Washington, Bellevue, WA, 10University of Pennsylvania, Philadelphia, PA, 11UCSF, San Rafael, CA, 12San Francisco VA/University of California, San Francisco, San Francisco, CA, 13VA Puget Sound Health Care System/University of Washington, Seattle, WA, 14New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 15VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA

    Background/Purpose: Frailty is a state of decreased physiological reserve that confers an increased vulnerability to stressors and adverse outcomes1. Compared to the general population, frailty…
  • Abstract Number: 1350 • ACR Convergence 2024

    Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis

    Tulsi Joishy, Sheau-Chiann Chen, Qiong Wu and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting the joints that is associated with increased cardiovascular risk. Environmental factors play a crucial role…
  • Abstract Number: 1366 • ACR Convergence 2024

    Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study

    Cécile Gaujoux-Viala1, Emmanuelle Dernis2, Eric Senbel3, Hélène Herman-Demars4 and René-Marc Flipo5, 1CHU Nîmes, Nïmes, Languedoc-Roussillon, France, 2CH LE MANS, LE MANS, Pays de la Loire, France, 3Cabinet de Rhumatologie, Marseille, France, 4Nordic Pharma France, Paris, France, 5CHU Lille, Lille, Nord-Pas-de-Calais, France

    Background/Purpose: Methotrexate (MTX) is the first line standard of care for the management of rheumatoid arthritis (RA). In the event of an inadequate response to…
  • Abstract Number: 1383 • ACR Convergence 2024

    Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis

    Huaqun Zhu1, Gong cheng1, yingni Li1, Yun Li1, Feng Sun1, Hongyan Wang1, Qinqin li2, Zhilun Li3, Ru Li4 and Zhanguo Li5, 1Peking University People's Hospital, Beijing, China, 2Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, China (People's Republic), 3Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, 4Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 5People’s Hospital Peking University Health Sciences Centre, Beijing, China

    Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…
  • Abstract Number: 1399 • ACR Convergence 2024

    A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA

    Karin Franck-Larsson1, Susanne Lindquist2, Agneta Wennerholm3, Johan Kolmert4, Maria Wanderoy3 and Olle Hernell2, 1Lipum AB, Uppsala, Sweden, 2Lipum AB; Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden, 3Lipum AB, Stockholm, Sweden, 4Lipum AB; Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Bile Salt-Stimulated Lipase (BSSL) is a lipolytic enzyme secreted by the lactating mammary gland and exocrine pancreas. Elevated plasma levels of BSSL have been…
  • Abstract Number: 1678 • ACR Convergence 2024

    Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study

    Eric Jenkins1, Ingrid Louw2, Attila Balog3, Elsa van Duuren4, diane Horowitz5, Janusz Jaworski6, Alan Kivitz7, Ilona Kemplerne Ujfalussy8, Joe Pirrello1, Eben Tessari1, Sheldon Wang1 and John F Paolini1, and KPL-404-C211 Investigators, 1Kiniksa Pharmaceuticals, Lexington, MA, 2Panorama Medical Centre, Cape Town, South Africa, 3Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary, 4The Sefako Makgatho Health Science University, Pretoria, South Africa, 5Feinstein Institute for Medical Research, New York, NY, 6Reumatika-Centrum Reumatologii, Warszawa, Poland, 7Altoona Center for Clinical Research, Duncansville, PA, 8Medical Centre, Hungarian Defense Forces, Dózsa György út 112, Budapest, Hungary

    Background/Purpose: Rheumatoid arthritis (RA) patients (pts) with inadequate response or intolerance to current biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have limited options. Abiprubart, a humanized…
  • Abstract Number: 1785 • ACR Convergence 2024

    Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation

    Martin Stradner1, Fernanda Monedeiro2, Elmar Zuegner2, Barbara Prietl3, Monika Oberhuber4, Michael Khalil5, Christoph Magnes2, Hans-Peter Brezinsek1, Angela Libiseller3 and Thomas Pieber3, 1Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 2Joanneum Research, Graz, Austria, 3Div. of Endocrinology, Medical University of Graz, Graz, Austria, 4CBmed, Graz, Austria, 5Dept. of Neurology, Medical University of Graz, Graz, Austria

    Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases.  Here…
  • Abstract Number: 1894 • ACR Convergence 2024

    Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System

    Gregory McDermott1, Mark Hammer2, Xiaosong Wang3, Misti Paudel4, Sung Hae Chang5, Pierre-Antoine Juge6, Qianru Zhang7, Jessica Lorusso8, Amie Samulyov8, Kathleen Vanni2, Alene Saavedra2, Emily Kowalski2, Grace Qian3, Katarina Bade2, Kevin Mueller2, Jeffrey Sparks9 and Suzanne Byrne2, 1Brigham and Women's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, 6Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 7Harard Medical School, Cambridge, 8Mass General Brigham, Boston, MA, 9Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Cigarette smoking is a risk factor for both lung cancer and RA. Furthermore, RA is associated with pulmonary abnormalities including interstitial lung disease, bronchiectasis,…
  • Abstract Number: 1985 • ACR Convergence 2024

    Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans

    Madeline O’Sullivan1, grant Cannon2, Sauer brian3, Jorge Rojas4, Gary Kunkel5, Jessica A Walsh6, Punyasha Roul7, shardool Patel1, Joshua Baker8, Bryant England9 and Tawnie Braaten1, 1University of Utah, Salt Lake City, UT, 2University of Utah and Salt Lake City VA, Salt Lake City, UT, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4Seattle VA, Mexico, Mexico, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 7UNMC, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA, 9University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology